Accelerate New York Seed Fund

Cress Health focuses on creating innovative digital solutions aimed at improving mental wellness for both individuals and organizations. The company's healthcare platform allows users to track their daily emotions and connect with peers, facilitating the sharing of experiences. By providing personalized reports, Cress Health enables users to gain a deeper understanding of their mental health, fostering self-awareness and support within a community framework. Through these offerings, Cress Health seeks to disrupt traditional approaches to mental wellness, making it more accessible and engaging for users.

Fuell is a manufacturer of premium electric mobility solutions aimed at providing alternatives to traditional cars. The company focuses on creating an urban mobility experience tailored to the needs of city riders, emphasizing safety and advanced technology. By integrating electric powertrains, Fuell designs e-vehicles that enhance urban riding pleasure while offering digital services to enrich the overall mobility experience. The founders leverage their diverse expertise to develop innovative solutions that cater specifically to the challenges of urban transportation.

Qunnect, LLC specializes in developing modular light-based devices that facilitate the transmission, storage, and reception of encrypted information, aimed at creating large-area ultra-secure networks. Utilizing principles of quantum physics, these devices ensure that any attempt to observe the data alerts both the sender and recipient, thereby enhancing cybersecurity. Founded in 2017 and based in Stony Brook, New York, Qunnect emerged as a spin-off from the Quantum Information Technology group at Stony Brook University. The company's focus is on engineering advanced quantum memories and sources, which are crucial for future information networks and quantum computing. Additionally, Qunnect offers field-deployable hardware systems for optical and long-distance communication, along with an AI-enabled software suite that allows for real-time monitoring of network components. This innovative approach positions Qunnect at the forefront of evolving cyber-security markets by enabling sophisticated and scalable quantum-secure communication solutions.

Goldilocks Therapeutics is a biopharmaceutical company focused on developing preventative treatments for acute kidney injury and polycystic kidney disease, among other renal conditions. Founded in 2018 and headquartered in Bedford, New York, the company utilizes its proprietary mesoscale nanoparticles to specifically target therapeutic payloads to the renal tubule epithelium. This innovative approach allows for sustained-release delivery of treatments, aiming to enhance patient outcomes and improve the quality of life for individuals suffering from these kidney-related ailments.

CalmiGo specializes in developing a portable, drug-free device aimed at providing immediate relief from emotional and mental distress, such as anxiety and stress. Utilizing advanced patented technology, the device helps users regulate their breathing patterns and stimulates their senses to alleviate symptoms on the spot. It is designed for ease of use, making it accessible to individuals of all ages and varying technical abilities, regardless of their location. By offering a natural solution, CalmiGo addresses the need for effective stress management without reliance on pharmaceuticals.

HashLynx Inc. is a company founded in 2018 and based in Middletown, New York, that specializes in designing and developing a platform for trade matching and settlement in capital markets. The firm aims to enhance the efficiency and transparency of these markets by utilizing advanced blockchain solutions and financial expertise. HashLynx offers a seamless, open-architecture platform that integrates with existing front- and back-end legacy loan systems. By leveraging smart contract technology, the company significantly reduces both the time and cost associated with syndicated lending transactions, thereby improving overall operational effectiveness for its clients.

Aspisafe Solutions is a medical device company that specializes in developing innovative feeding medical devices, including catheters, feeding tubes, and nasogastric tubes. The company’s flagship product is a nasogastric tube designed to prevent stomach reflux, thereby reducing the risk of aspiration and pneumonia in intubated patients. Utilizing proprietary balloon pressure technology, this device works harmoniously with the patient's anatomy to secure and maintain the intubation catheter comfortably. Aspisafe Solutions aims to address critical healthcare challenges associated with feeding and ventilation in vulnerable patient populations.

Toggle is a company based in the United States that specializes in robotics and automation solutions for the construction industry. It offers a robotics as a service (RaaS) platform specifically designed for assembling rebar cages used in reinforced concrete applications. Utilizing advanced two-arm robotic platforms and proprietary jig designs, Toggle's technology enables the construction of rebar structures directly from computer blueprints, allowing for precise and efficient pre-assembly services.

TargaGenix Inc. is a biotechnology company based in Stony Brook, New York, founded in 2013. The company focuses on developing innovative compounds targeting drug-resistant tumors and cancer stem cells. Its lead product, SBT-1214, has demonstrated the ability to completely eliminate tumors in various preclinical models, including those for colon, pancreatic, prostate, breast, and lung cancers. SBT-1214 also effectively down-regulates gene expression associated with stemness, aiding in the elimination of cancer stem cells. The product features additional chemical modifications and a novel fatty-acid based nanoemulsion formulation, which enhance its pharmacokinetic and pharmacodynamic properties while reducing toxicity.

EpiVax Oncology Inc. specializes in developing precision cancer immunotherapies focused on mutanome-directed and neo-epitope personalized treatments. Founded in 2017 and based in New York, the company offers advanced immuno-oncology solutions and neoantigen discovery services. Its research and development platform utilizes proprietary in-silico predictive algorithms to select optimal neo-epitopes, allowing clients to tackle unmet medical needs in cancer treatment that existing therapies do not adequately address.

Concarlo Therapeutics is a preclinical-stage oncology company focused on developing innovative therapies for drug-resistant cancers. The company aims to transform cancer into a treatable and manageable condition by targeting p27, a natural inhibitor of key cell cycle regulators CDK4/CDK6 and CDK2. Leveraging extensive research, Concarlo seeks to exploit a unique cellular pathway to effectively kill tumor cells rather than merely halting their growth. Its approach emphasizes precision medicine, particularly in managing breast cancer, while also addressing various advanced and orphan cancers such as ovarian and pancreatic cancers. By enhancing drug efficacy and minimizing toxicity, Concarlo Therapeutics aims to provide significant benefits to cancer patients, particularly those facing metastatic disease.

Frenzy Labs, Inc. is a technology company that specializes in developing a visual search application platform to enhance image monetization for websites. Founded in 2017 and based in Marina Del Rey, California, Frenzy utilizes deep learning algorithms and computer vision to analyze website images, accurately identifying brands and products even in complex visual scenes without logos. The company offers various solutions, including self-labeling image technology that significantly reduces the need for manual labeling, thereby improving efficiency in managing image datasets. Frenzy's products include Fetch, a content monetization plugin tailored for fashion bloggers, and Frenzy Enterprise Solutions, which provides automated catalog management and precise image search capabilities for e-commerce platforms. By enabling users to seamlessly monetize their site images, Frenzy helps streamline the online shopping experience while minimizing the time and effort required to identify products.

Mirow LLC, founded in 2016 and based in New York, specializes in manufacturing smart mirrors for fitting rooms in retail and hospitality settings. These interactive mirrors utilize touch technology and sensors to enhance the shopping experience by providing personalized recommendations, information on discounts and special offers, and the ability to request assistance from sales staff. Customers can also inquire about items in different sizes or colors. Mirow's innovative approach not only improves customer service but also generates valuable insights into consumer behavior. The company has received recognition in the industry, being featured in notable publications and included in influential retail technology maps. Mirow is expanding its presence in both the United States and European markets, serving a diverse range of high-profile clients.

Digitouch Health is a U.S.-based company located in Valhalla, New York, that specializes in the development of a smartphone device for monitoring blood pressure. This innovative medical device utilizes algorithm-enabled technology and oscillometry to measure hypertension accurately without the need for calibration. It allows users to conveniently track and transmit their blood pressure readings to electronic health records, facilitating better management of cardiovascular health. By collaborating with healthcare practitioners, Digitouch Health aims to help individuals lead longer and healthier lives through effective monitoring and management of their blood pressure.

Bioharmony Therapeutics, Inc. is engaged in the development of lysin-based antimicrobial therapeutics aimed at addressing multi-drug resistant Gram-negative bacterial infections. Established in 2016 and headquartered in New York, the company focuses on creating innovative treatments that target skin infections caused by multi-drug resistant Acinetobacter baumannii. These therapeutics utilize bacteriophages to effectively break down bacterial cell walls, which may also assist in treating more severe conditions such as hospital-acquired pneumonia and life-threatening blood or wound infections. Bioharmony Therapeutics is committed to providing solutions for patients facing challenging bacterial infections resistant to conventional antibiotics.

DepYmed, Inc. is a pharmaceutical company based in Cold Spring Harbor, New York, focused on developing therapeutics for breast cancer and rare diseases. The company specializes in inhibitors of the enzyme PTP1B (protein tyrosine phosphatase 1B), particularly for treating HER2-positive breast cancer. Its development portfolio includes MSI-1436C (Trodusquemine), a potent PTP1B inhibitor. Additionally, DepYmed has created a range of novel small molecules with copper-chelating properties, which may serve as therapeutic agents for various conditions, including Wilson Disease and cancer. Currently, the company is advancing the development of next-generation PTP1B inhibitors and selective copper chelators in preclinical studies, collaborating with Cold Spring Harbor Laboratory. DepYmed is also exploring further therapeutic indications that could benefit from these innovative agents.

PainQx, Inc. is a diagnostic and software company that specializes in developing innovative healthcare solutions for both human and veterinary applications. Founded in 2015 and based in New York, the company has created the PainQx System, a platform that objectively measures pain by analyzing neural activity from a patient’s brain. Utilizing proprietary algorithms, the system processes EEG data to produce a scaled pain and neurological side effects biomarker that correlates directly with a patient's pain state. This technology serves as a clinical assessment tool for organizations that require accurate pain measurement in clinical trials, particularly where pain is a primary or secondary endpoint for evaluating the efficacy of drugs or medical devices. PainQx operates on a pay-per-use or subscription model, making its advanced diagnostic capabilities accessible to a broad range of healthcare providers.

Paladin is a legal technology company founded in 2015 and based in New York, USA. The firm has developed a platform that connects attorneys with vetted pro bono opportunities, allowing legal professionals to engage in cases that align with their passions. By streamlining the process of creating, distributing, and managing pro bono matters, Paladin enables law firms, bar associations, and corporations to enhance their service delivery to low-income individuals. Additionally, the platform facilitates the tracking of lawyers' contributions and captures impact data, highlighting the positive effects of their efforts. Through its services, Paladin aims to enhance pro bono participation and support the legal community in addressing access to justice.

ENB Therapeutics is a biopharmaceutical company focused on developing small molecule inhibitors aimed at treating melanoma and other cancers. Founded in 2015 and headquartered in New York, the company’s lead product, ENB-001, is a selective endothelin B receptor (ETBR) inhibitor. This innovative therapy has shown promise in preclinical studies to reduce tumor growth and enhance survival rates in cancer models by restoring T-cell infiltration into tumors and inhibiting metastasis. ENB-001 has received Orphan Drug Designation from the FDA, ensuring market exclusivity and strong intellectual property protection. The company is also developing a companion diagnostic to identify patients with over-expressed ETBR pathways, which may allow for expansion into multiple tumor types. By addressing drug resistance commonly seen in cancer patients, ENB Therapeutics aims to establish new standards of care that enhance the effectiveness of existing immunotherapy treatments and improve patient outcomes.

Mymee, Inc. is a New York-based company that specializes in remote care and support services for individuals with chronic rheumatic and neurological autoimmune diseases. Founded in 2011, Mymee has developed a software-as-a-service health coaching platform that identifies non-obvious triggers for symptoms through personalized analysis of users' daily lives. The platform focuses on dietary and environmental factors that may contribute to disease flares and creates tailored care plans to address these triggers. By combining expert health coaching with behavioral change strategies, Mymee aims to enhance the quality of life for its users. Clinical trials have shown that participants experience significant improvements in various health-related quality of life domains, including fatigue and pain. Through the support of certified health coaches, Mymee empowers individuals to take control of their health and adopt habits that may help reverse their symptoms.

Marvel Genomics focuses on developing genetic tests to identify young children at risk for autism, facilitating early intervention to enhance outcomes. The company specializes in genomic diagnostics and has created a proprietary device aimed at detecting Copy Number Variation, which helps pinpoint children who may be at risk for autism and other genetic disorders. By providing precise genetic assessments, Marvel Genomics enables timely diagnosis and access to appropriate treatments and therapies, thereby improving the potential for successful intervention in affected individuals.